Technology Innovation Institute Introduces World’s Most Powerful Open LLM: Falcon 180B
6.9.2023 16:20:00 EEST | Business Wire | Press release
The Technology Innovation Institute (TII) in the United Arab Emirates (UAE) is pushing the boundaries of generative AI once again with the launch of Falcon 180B, an advanced iteration of its flagship large language model (LLM). This groundbreaking release strengthens the UAE's dominance in AI, offering Falcon 180B as an open access model for research and commercial purposes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230906583274/en/
Falcon 180B Benchmarks (Photo: AETOSWire)
Following the remarkable success of Falcon 40B, an open source AI model that swiftly ascended to the top of the Hugging Face Leaderboard for LLMs in May 2023, TII, the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC) continues to lead the charge in generative AI. Falcon 40B marked one of the first instances of open source models for both researchers and commercial users, and it was considered a pioneering leap in the field.
H.E. Faisal Al Bannai, Secretary General of the Advanced Technology Research Council, emphasized the positive impact of Falcon on the AI landscape and said: “We envision a future where the transformative power of AI is within everyone's reach. We are committed to democratizing access to advanced AI, as our privacy and the potential impact of AI on humanity should not be controlled by a select few. While we may not have all the answers, our resolve remains unwavering: to collaborate and contribute to the open source community, ensuring that the benefits of AI are shared by all.”
With a staggering 180 billion parameters and trained on 3.5 trillion tokens, Falcon 180B soars to the top of the Hugging Face Leaderboard for pretrained LLMs. It outperforms notable competitors like Meta’s LLaMA 2 in various benchmarks, including reasoning, coding, proficiency, and knowledge tests.
Among the best closed source LLMs, Falcon 180B ranks just behind OpenAI's latest GPT 4 and is on par with the performance of Google's PaLM 2 Large, the model powering Bard – despite being half the size of the model. The licensing framework for the model is established on ‘Falcon 180B TII License’, which is based upon Apache 2.0.
Dr. Ebtesam Almazrouei, Executive Director and Acting Chief Researcher of the AI Cross-Center Unit at TII, said: "The launch of Falcon 180B exemplifies our dedication to advancing the frontiers of AI, and we are thrilled to share its limitless potential with the world. Falcon 180B heralds a new era of generative AI, where the potential of scientific advancement is made available through open access to fuel the innovations of tomorrow. As we delve into frontiers of science and technology, our vision extends far beyond innovation; it's about nurturing a profound connection to address global challenges through collaborative breakthroughs.”
With over 12 million developers adopting and deploying the first release of Falcon, this significant upgrade is poised to become the premier model for various domains, from chatbots to code generation, and beyond.
Falcon 180B is compatible with the following major languages: English, German, Spanish, and French, with limited capabilities in Italian, Portuguese, Polish, Dutch, Romanian, Czech, and Swedish.
For more information, please visit FalconLLM.tii.ae
Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230906583274/en/
Contact information
Jennifer Dewan, Senior Director of Communications
jennifer.dewan@tii.ae.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom